Strides Shasun receives USFDA tentative approval for Roflumilast Tablets

01 Jun 2016 Evaluate

Strides Shasun has received tentative approval from the United States Food & Drug Administration (USFDA) for Roflumilast Tablets, 500 mcg. The product received approval in 15 months under the new GDUFA goal date regime. The product can be launched earliest by January 2020.

According to IMS data, the US market for Roflumilast Tablets 500 mcg is approximately $ 174 Million. Roflumilast tablets registered a healthy growth of 16% in value terms and 5% in volume terms in US (IMS March 2016 MAT data). Based upon available information, company believes it is amongst the first wave of ANDA applicants for Roflumilast with a Paragraph IV certification, which is under litigation as per the provisions of the Hatch-Waxman Act. On receiving full approval, the product will be manufactured at the company's Oral dosage facility at Bangalore and marketed by the company in the US Market.

Roflumilast Is used to prevent worsening of symptoms In people with severe chronic obstructive pulmonary disease (COPD)

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and and semi-solids.

Strides Pharma Scien Share Price

902.20 -8.25 (-0.91%)
29-Dec-2025 13:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1723.00
Dr. Reddys Lab 1267.30
Cipla 1499.40
Zydus Lifesciences 904.05
Lupin 2095.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×